Tempest Therapeutics (TPST) Stock: Buy, Sell, or Hold?
TPST - Tempest Therapeutics, Inc. Common Stock
$0.51
-0.01 (-2.16%)
▼
5d:
-18.14%
30d:
-39.88%
90d:
-45.32%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 04, 2026
10d
Get Alerted When TPST Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TPST is down 18.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TPST is down 18.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TPST is currently trading at $0.51, which is considered oversold relative to its 30-day fair value range of $0.63 to $0.92.
Technical Outlook: Technically, TPST is in a strong downtrend. The price is currently testing key support at $0.50. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TPST scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+1269.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TPST is in a strong downtrend. The price is currently testing key support at $0.50. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TPST scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+1269.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.63 -
$0.92
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1269.9% below Wall St target ($7.00)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.63 -
$0.92
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.50
Resistance Level
$0.78
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.57
Wall Street Target
$7.00
(+1269.9%)
Share & Embed Analysis
Last updated: October 24, 2026 6:52 AM ET
Data refreshes hourly during market hours. Next update: 7:52 AM
Data refreshes hourly during market hours. Next update: 7:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TPST showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 53 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 64 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 48 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 59 HOLD |
|
CGON
CG Oncology, Inc. Common… |
STRONG BUY
15 analysts |
$91 | 64 BUY |
